Head-To-Head Contrast: Scienture (SCNX) vs. Its Competitors

Scienture (NASDAQ:SCNX) is one of 248 public companies in the “MED – DRUGS” industry, but how does it contrast to its competitors? We will compare Scienture to similar businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.

Earnings & Valuation

This table compares Scienture and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scienture	$653,391.00	$9.07 million	-0.53
Scienture Competitors	$29.77 billion	$56.31 million	3.60

Scienture’s competitors have higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Scienture and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-24.47%	-19.30%
Scienture Competitors	-21,934.00%	-158.76%	-18.03%

Volatility and Risk

Scienture has a beta of 3.04, suggesting that its share price is 204% more volatile than the S&P 500. Comparatively, Scienture’s competitors have a beta of 1.28, suggesting that their average share price is 28% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Scienture and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Scienture Competitors	2062	3753	9785	404	2.53

As a group, “MED – DRUGS” companies have a potential upside of 60.56%. Given Scienture’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Scienture has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 21.4% of Scienture shares are owned by company insiders. Comparatively, 13.4% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Scienture competitors beat Scienture on 9 of the 13 factors compared.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.